Aarti Industries — A Long Wait for the Cycle to Turn

The State of Play

Aarti Industries turns benzene and toluene into a long list of specialty chemicals that end up in crop protection, plastics, dyes, fuel additives and pharmaceuticals. For about four years it has been stuck in the same trap: revenue keeps climbing on volume, but profit sits at roughly a third of its FY22 peak, squeezed flat by a relentless wave of cheap Chinese supply and the loss of a big long-term contract. FY26 (ended March 2026) was the first real glimmer of a turn — full-year profit up 27% to ₹419 crore, helped by a US–India trade deal and China beginning to rein in its own overcapacity — but the recovery is fragile, leverage has climbed to an uncomfortable 3.6 times EBITDA, and a fresh Middle East war spiked raw-material costs just as the year ended. The stock, at 40 times earnings, is priced for a recovery the numbers have only just begun to show.

The Company

Aarti is the flagship of the Aarti group, making organic and inorganic specialty chemicals across plants in Gujarat (Vapi, Jhagadia, Dahej, Kutch) and Maharashtra (Tarapur). Its calling card is a leading position in NCB-based chemistry (nitrochlorobenzenes), and a broad downstream catalogue spanning agrochemical intermediates, dyes and pigments, polymers and additives, and a large and growing “energy”/fuel-additives business (MMA — methyl methacrylate-linked — and others). End markets are roughly: energy ~40%, with agrochem, polymers and pharma making up most of the rest. It is heavily export-oriented (exports run 55–65% of revenue) and, by its own reckoning, roughly 70–75% of its product basket competes directly against Chinese supply — which is the single most important fact about the business right now.

This is a capital-hungry manufacturer mid-build: fixed assets have grown to ₹6,556 crore with another ₹2,030 crore of plants under construction. Free cash flow has been negative through the capex cycle, borrowings have climbed to ₹4,966 crore, and returns are currently thin (ROCE ~6.9%, ROE ~7.1%) — all symptoms of spending ahead of a recovery.

A leadership change frames the period: founder Rajendra Gogri stepped down as CEO in June 2024, handing operations to a professional CEO, Suyog Kotecha, while staying on as chairman. The recent calls are Kotecha’s, with CFO Chetan Gandhi.

On ownership, foreign funds have cut hard — from over 12% to a 6.3% low before a small recovery to 7.4% — while domestic institutions absorbed most of it (up to ~20%). Promoter holding has drifted gently down to 42.09%.

The Story So Far

The arc across three annual reports and four FY26 calls is a single, painfully long down-cycle, with the first signs of a turn arriving only at the very end.

FY23 — the “Golden Decade,” already cracking

The FY23 report still carried optimistic “Golden Decade” framing, but the cracks were visible. Revenue was ₹7,283 crore, EBITDA ₹1,089 crore, profit ₹545 crore — already roughly half the FY22 figure. Two structural events shaped the year: the demerger of the pharma business (Aarti Pharmalabs) completed, leaving Aarti a pure specialty-chemicals play; and the earlier termination of a major long-term agrochem (herbicide) contract, the same event that had produced a distorting one-time ~₹631 crore gain back in FY22 (and whose absence makes every subsequent year look weak by comparison). The big forward bet was launched here: Zone IV, a multi-block chlorotoluene-value-chain expansion budgeted at ₹2,500–3,000 crore through FY26, with first commissioning promised for “H2 FY25.”

FY24 — “Resilient Path,” and China named as the villain

FY24 was openly defensive. Revenue slipped to ₹7,012 crore and profit fell again to ₹416 crore. For the first time the annual report named Chinese oversupply explicitly as a margin driver — most starkly in polymers, where volume rose 18% but value fell 6%. The company kept signing long-term contracts to shore up visibility (a ₹6,000 crore four-year deal and a ₹3,000 crore nine-year agrochem deal), cut its dividend to ₹1, and — the recurring theme — pushed Zone IV’s first commissioning out to “FY26.” This was also the year of the CEO handover.

FY25 — a new revenue high, a new profit low

FY25 (the first “Integrated Report”) captured the paradox cleanly: revenue recovered 15% to a record ₹8,046 crore, but profit fell again to ₹331 crore — the lowest of the three years. China was now “exporting at unprecedented levels,” and management was openly calling for anti-dumping duties and BIS quality norms to level the field. The energy/fuel-additives segment became the largest at ~36%. New JVs firmed up (Augene with UPL/Superform, and a recycling JV); Zone IV slipped again, now to “FY27 ramp-up.” The pattern by this point was unmistakable: top line grinding higher, bottom line ground down by Chinese pricing, and the flagship capex project perpetually a year away.

Q1 FY26 (call of 1 August 2025) — “one of the more complex quarters”

The current year opened badly. Revenue fell 16% sequentially to ₹1,867 crore; EBITDA dropped to ₹215 crore (dented by ~₹45–50 crore of one-off inventory and deferred-shipment hits); profit was just ₹43 crore. A new US tariff (25% on Indian imports) landed on a business with 15–20% direct US exposure. Two things stood out. First, management made a deliberate choice that defines the period: it abandoned annual EBITDA guidance entirely, committing only to a three-year aspiration:

“Yearly guidance is a practice from which we are moving away… we would like to continue to maintain the same practice.” — Suyog Kotecha, CEO

The only number it would stand behind was a FY28 EBITDA run-rate of ~₹1,800 crore, built from cost savings, capex-led EBITDA, and operating leverage. Second, it insisted raw materials (benzene, aniline) had “practically bottomed out.”

Q2 FY26 (call of 7 November 2025) — volumes recover, US rerouted

A sharp bounce: revenue up 21% to ₹2,250 crore, EBITDA up 36% to ₹292 crore, profit ₹106 crore. MMA hit its highest-ever quarterly volumes, and the company nimbly rerouted exports away from a tariff-hit US toward Europe, the Middle East and Africa — “no revenue loss,” because volume replaced volume. Kotecha claimed the debt-to-EBITDA ratio “could have already seen the peak” — a confident, checkable statement that the year would not be kind to.

Q3 FY26 (call of 3 February 2026) — three tailwinds at once

The strongest quarter of optimism. Revenue rose 11% to ₹2,492 crore, EBITDA to ₹323 crore, profit to ₹133 crore, with exports at a record ~65%. Management led with three external tailwinds: an India–EU trade deal concluded; a US–India trade deal that cut the tariff from 50%+ down to 18%; and — most structurally — China’s “anti-involution” push, including removing a 13% VAT rebate on exports of several chemistries (including NCB), which lifted NCB pricing 7–10% “within days.” Kotecha framed anti-involution as “a structural catalyst for sustainable margin recovery.” FY26 capex was revised up to ~₹1,100 crore.

Q4 FY26 (call of 5 May 2026) — a turn, then a war

The year closed with a recovery and a fresh shock. Full-year FY26 came in at revenue ₹9,018 crore (+12%), EBITDA ₹1,172 crore (+15%) and profit ₹419 crore (+27%) — the first genuine profit recovery in years. Two new long-term contracts validated the model: a 15-year backward-integration deal with a global major (~₹200–250 crore capex, fixed additional margin) and a $150 million multi-year supply agreement with a global agrochem innovator through 2030 (no incremental capex). But the quarter was overshadowed by a war in the Middle East: benzene, aniline, toluene and methanol prices jumped over 60%, freight spiked, and shipments to the region (~9–10% of revenue) stopped for six to eight weeks. The “full impact,” management warned, would land in Q1 FY27.

How did the promises hold up?

• “Debt-to-EBITDA has peaked” (Q2) → missed; net debt actually rose to ~₹4,300 crore by year-end (3.6x EBITDA), blamed on raw-material-driven working capital. A fresh pledge: down to 2.5x within two years.
• Zone IV first commissioning → slipped from “H2 FY25” (FY23) to “December 2025” (Q1) to a 3–4 month delay on a contract-labour shortage, with first revenue now “as early as Q2 FY27.”
• FY28 ₹1,800 crore EBITDA target → never revised, but in Q4 management conceded the capex-led slice may arrive ~6–7 months late because of the Zone IV delay.
• FY26 capex “below ₹1,000 crore” (Q1) → crept up to ₹1,125 crore delivered.

Where Things Stand

As of the May 2026 call, Aarti is a business where the external weather has finally started to improve but the boat is still heavy. The genuinely positive shifts are real and largely outside its control: the US tariff cut to 18%, the India–EU deal, and above all China’s anti-involution measures, which — if they persist — directly relieve the pricing pressure that has crushed Aarti’s margins for four years (the NCB benefit is expected to flow from Q1 FY27). Against that, the near-term is messy: the Middle East war’s raw-material spike will hit Q1 FY27, leverage is high at 3.6x and dependent on both rising EBITDA and calmer crude to come down, the flagship Zone IV project is still ramping (a two-year journey to fill), and returns remain well below the company’s own history. Management has deliberately stopped giving annual guidance, asking investors to judge it against a FY28 EBITDA run-rate of ₹1,800 crore — a target it still holds, even as it admits the timing has slipped. The story, in short: the cycle may finally be turning, but Aarti is asking for patience measured in years, not quarters.

The Four Checks

1. Quality and moat. A capable manufacturer with an edge, but not a protected one. The moat, such as it is, rests on complex benzene-chain chemistry done at scale (a leading position in NCB-based products), regulatory and safety credentials that keep global majors coming back — the FY26 year alone brought a 15-year backward-integration deal with a repeat global customer and a $150 million agrochem supply agreement through 2030 — and four decades of integrated plants across Gujarat and Maharashtra. But the past four years are the stress test, and the verdict is plain: roughly 70–75% of the product basket competes directly with Chinese supply, and when China flooded the market, Aarti’s operating margin fell from the 22–28% band of FY19–FY22 to 14% and stayed there. A business whose profitability depends this heavily on Chinese export policy (the current relief comes from Beijing’s “anti-involution” measures, not anything Aarti did) has customer stickiness and process depth, not pricing power.

2. Returns on incremental capital and runway. Currently poor, with a promise attached. ROCE has compressed from 22% in FY22 to 10%, 7%, 6% and 7% in the four years since; ROE sits at 7.1%. Over that same stretch the company poured roughly ₹1,300–1,400 crore a year into capex — fixed assets are now ₹6,556 crore with another ₹2,030 crore under construction — so the recent record is large sums deployed at returns well below the cost of capital. The case for better incremental returns rests on Zone IV (new chlorotoluene chemistries pitched at 25–30% EBITDA margins) and the FY28 EBITDA target of ~₹1,800 crore, but Zone IV has slipped from “H2 FY25” to “Q2 FY27 first revenue” across three annual reports, and the margin claims are untested. The runway is real — 35–40 new products, a long import-substitution list — but the demonstrated return on the last five years of reinvestment is mid-single digits.

3. Capital allocation for the stage. Mixed, leaning aggressive. Management kept spending hard through a brutal down-cycle — capex ran ₹1,306 crore (FY23), ₹1,358 crore (FY24), ₹1,408 crore (FY25) and ₹1,125 crore (FY26), all of it free-cash-flow negative and funded by borrowings that climbed from ₹2,874 crore to ₹4,966 crore — while the dividend was cut to ₹1 per share (payout ~9% of profit) and no buybacks appear anywhere in the record. There is no dilution and no diworsification (the pharma demerger actually sharpened focus), and the new contract-backed capex is sensibly small. But the track record on financial promises is weak: net debt was supposed to fall ₹200–300 crore in FY26 and the CEO said leverage had “already seen the peak” — instead net debt rose to ~₹4,300 crore, 3.6x EBITDA. Reinvesting hard would be the right call for this stage if incremental returns were high; at 7% ROCE and 3.6x leverage, it is a bet that the cycle turns before the balance sheet tires.

4. Price. Demanding. As of the June 2026 snapshot, the stock trades at ₹436 — a market cap of ₹15,795 crore, 38.3 times earnings and 2.64 times book — against a business earning 6.9% ROCE, 7.1% ROE, carrying net debt at 3.6x EBITDA, and paying a 0.23% dividend yield. The multiple only works if FY26’s profit recovery (₹419 crore, +27%) compounds into something like the FY28 ₹1,800 crore EBITDA aspiration, Chinese pricing discipline holds, and the Middle East raw-material spike that management says will hit Q1 FY27 proves temporary. That is a lot of external weather to need. The price assumes the turn; the numbers so far show only its first quarter.

Sources

• Earnings-call transcripts read (4): Q1 FY26 (1 Aug 2025), Q2 FY26 (7 Nov 2025), Q3 FY26 (3 Feb 2026), Q4/FY26 (5 May 2026). From screener/BSE-hosted filings.
• Annual reports read (high-signal sections + targeted full-text reads): FY23, FY24, FY25.
• Financial snapshot: screener.in (consolidated, AARTIIND), logged-out session, fetched 2026-06-07. Note: management’s reported revenue (FY26 ₹9,018 crore; quarterly ₹1,867 / 2,250 / 2,492 / 2,422 crore) runs above screener’s net-sales line (FY26 ₹8,286 crore) on a definitional basis; the profit figures (FY26 ₹419 crore) reconcile. The chronicle uses management’s reported figures for the quarter-by-quarter narrative.
• Research dump: vault/Sources/Earnings/Aarti Industries Ltd/ (_profile_digest.md, _concall_digest.md, _ar_digest.md, raw transcripts, annual-report sections, _snapshot.json, _manifest.json). Not published.